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Abstract
The development of intervention strategies for carriers of mutations in the BRCA1 and
BRCA2 genes has several considerations. The first are primary prevention and secondary
prevention in unaffected carriers using medical/surgical or lifestyle strategies to prevent
cancer development, or screening methods to detect cancers at an earlier stage. The
options available are determined by the magnitude and age at onset, risk profile of cancer in
carriers (the penetrance function of the gene) and the different cancer sites involved. The
management of affected individuals who are BRCA1 and BRCA2 mutation carriers may be
altered by their carrier status, because the tumour histology, efficacy of treatment and risk of
subsequent cancer development is determined by the BRCA1 and BRCA2 germline status.
Carriers of BRCA1 and BRCA2 mutations are relatively rare, so the strategies for
management should be determined by international multicentre studies.
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Introduction
About 5–10% of breast and ovarian cancers occur as a
result of highly penetrant germline mutations in cancer
predisposing genes [1,2]. Half of these are due to muta-
tions in BRCA1 or BRCA2 [3]. BRCA1 on chromosome
17q encodes a protein of 1863 amino acids [4•] and
BRCA2 on 13q is about twice the size of BRCA1 [5•].
Although deleterious mutations in both genes predispose
to earlier onset and an increased risk for female breast
cancer, the risk of cancers at other sites and the risk
profile differs for the two genes.
BRCA1 and BRCA2 genes and cancer risks
Collaborative studies by the Breast Cancer Linkage Con-
sortium (BCLC) have combined data from numerous fami-
lies with germline mutations in BRCA1 and BRCA2
worldwide to determine penetrance estimates and risks
for other cancers in BRCA1 and BRCA2 mutation carri-
ers. These have shown that both genes confer an
increased risk for female breast cancer of 80–85% by the
age of 80 years [6,7••], although the penetrance curve for
BRCA1 starts to rise slightly earlier than that for BRCA2
(Figs 1 and 2). Both genes confer an increased risk for
ovarian cancer, but the lifetime risks are higher for BRCA1
(60% by age 80 years) than for BRCA2 (27% by age 80
years; the population risk is just under 1%), and the pene-
trance curve also starts to rise earlier (late 30s) for
BRCA1 than for BRCA2 (mid 40s; Figs 1 and 2) [7].
It is now clear that both genes confer an increased risk for
prostate cancer, which is threefold for BRCA1 mutations
[8•] and threefold to sevenfold for BRCA2 mutationsBreast Cancer Research    Vol 2 No 4 Eeles
[9,10••], equating to an absolute risk of 6–14% by age 74
years; the population risk by this age is 2%. Mutations in
BRCA1 are also thought to increase the risk of colon
cancer to about 6% by age 70 years [8•], but carriers of
mutations in BRCA2 do not appear to be predisposed to
colon cancer.
A recent analysis of the risk of other cancers in BRCA2
carriers [10••] reported a significantly increased risk for
cancer of the prostate, stomach, pancreas, male breast,
head and neck, ocular melanoma, cutaneous melanoma
and fallopian tube, and cancer of the gallbladder and bile
duct. Because many of these latter cancers are rare in the
general population, the absolute risk is still low in BRCA2
carriers, and targeted screening at these sites, with the
exception of prostate cancer, is not warranted.
The ethnic origin of the BRCA1 or BRCA2 carrier is
important in refining these penetrance estimates. Studies
in Ashkenazi Jews and the Icelandic population have
reported lower lifetime penetrance estimates for breast
cancer of 50–60% in the Ashkenazim [11] and 37% in the
Icelandic population [12]. The risks of ovarian cancer are
also lower in the Ashkenazim [11] than in the overall
BCLC estimates.
Some researchers have reported a genotype–phenotype
correlation of mutation position and breast/ovarian cancer
risk [13], with mutations at the 5¢ end of BRCA1 and the
central part of BRCA2 conferring a higher risk for ovarian
cancer. What is unclear is whether this represents a
higher risk for ovarian cancer per se or a relatively lower
risk for breast cancer, and further studies within the BCLC
dataset are ongoing.
Table 1 summarizes the risks for cancers in BRCA1 and
BRCA2 mutation carriers [14].
Detection of BRCA1 and BRCA2 carriers
Over 200 distinct mutations in BRCA1 and BRCA2 have
been described, and are listed in a database on the Inter-
net [15–17]. These mutations are widely scattered across
both genes. Most mutations truncate the protein product,
but a significant proportion (34% of BRCA1 and 38% of
BRCA2 mutations [17]) are missense mutations that alter
one amino acid, but do not truncate the protein and are of
uncertain significance (so-called variants of uncertain sig-
nificance). At present, the cancer risks from such variants
are uncertain and most cancer geneticists would not offer
predictive genetic testing for such variants. It is likely that
some, but not all will transpire to be rare polymorphisms
(normal variants).
Because many different mutations have been described in
different families (apart from founder mutations in certain
populations such as the Ashkenazim and Icelanders
[18–21,22•,23]), when an individual wishes to know their
BRCA1 and BRCA2 carrier status, the mutation present
in the familial cancer cluster is first determined by mutation
screening of blood DNA from an affected family member
(diagnostic testing) and a predictive genetic test is then
offered to the unaffected family member who is seeking
testing when the mutation is identified. The predictive test
only ascertains whether the unaffected relative has that
specific mutation. It is recommended that predictive
genetic testing is preceded by full counselling of at least
two sessions, interspersed with a minimum 1-month
‘cooling off’ period, similar to the genetic testing protocol
for Huntington’s disease [24]. At present, the optimal
method of counselling for both affected and unaffected
members of the family is unknown; affected members who
give a blood sample to determine the mutation often
Figure 2
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Figure 1
BRCA1 breast/ovarian cancer risk.
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receive less counselling than the unaffected individual.
One may postulate that they may need more support,
because they have a cancer diagnosis that they then learn
has a genetic basis and this may have been passed on to
future generations. The counselling requirements of
affected persons need to be studied. The chance of a
mutation being present in BRCA1 or BRCA2 in certain
clusters is shown in Table 2.
Management of unaffected BRCA1 and BRCA2
mutation carriers
There are currently several approaches to the manage-
ment of men and women who are carriers of BRCA1 and
BRCA2 mutations. The options available depend on
whether the individual is already affected or is unaffected
with cancer. Broadly, for an unaffected carrier, these
options are as follows: early detection through screening
programmes; changes in lifestyle; chemoprevention; and
prophylactic surgery.
Early detection through screening
Breast screening
The value of mammographic screening for female carriers
of BRCA1 and BRCA2 mutations is currently under evalu-
ation. Population mammographic screening is offered in
the UK to those aged from 50 to 65 years every 3 years,
because this has been shown to reduce mortality by at
least 20% (for summary [26]). However, BRCA1 and
BRCA2 carriers are at risk for early-onset breast cancer,
and just over half of this risk occurs at ages before the
start of the screening programme. Guidelines for individu-
als who have a family history of breast cancer (not specifi-
cally  BRCA1 and  BRCA2 mutation carriers) have just
been compiled by the UK Cancer Family Study Group
[27]. Lalloo et al [28] have shown that mammographic
screening of a population aged under 50 years with a
family history (the genetic status was not determined)
detects as many cancers per 1000 women screened as
the UK National Breast Screening Programme. The
cancers detected were not all indolent preinvasive
tumours. However, no study has yet proven that targeted
screening of younger women with a family history of breast
cancer improves survival.
It is common practice to offer annual mammography from
ages 35–50 years in BRCA1 and BRCA2 carriers, but
the screening interval after 50 years is undefined. The
penetrance curves for breast cancer risk continue to rise
until ages 75–80 years, and so many clinics offer annual
mammography until the mid-70s. The screening interval in
women with a family history only (not BRCA1 and
BRCA2 carriers) is extended to 18 months after age 50
years. This is because, in the general population, invasive
interval cancers are more frequent among women aged
40–49 years than in older women, but this is not due to a
difference in the S-phase fraction in tumours in older
women [29].
If there is a very young individual (<30 years) with breast
cancer in the family, many units will start mammographic
screening at 30 years, but there is concern about radia-
tion-induced tumours if mammography is instigated any
younger than this. This is based on extrapolations from
atomic bomb radiation exposure data [30]. Furthermore, it
Table 1
Lifetime (by age 80 years) cancer risks (%) in BRCA1/BRCA2 mutation carriers
Cancer type
Gene Female breast Ovarian Male breast Colon Prostate*
BRCA1 80–85 60 ?0 6 6
BRCA2 80–85 27 5 ?0 6–14
*By age 74 years. Data from [14].
Table 2
Threshold for probability of BRCA1/BRCA2 mutation
Chance that
a mutation is
present* Clinical criteria
<10% All single cases of breast or ovarian cancer
10% Single breast cancer cases aged <35 years
>10–£30% Two breast cancer cases aged <50 years
One breast cancer case aged <40 years in an 
Ashkenazi jew
£50% Three breast cancer cases aged <50 years
Four to five breast cancer cases, no ovarian cancer
One breast and ovarian cancer case
>50% More than one breast and ovarian cancer case
At least four cases of female/male breast cancer
More than six female breast cancer cases
*The chance of detecting a mutation is lower, because at least 15% of
mutations are regulatory (ie they are not in the coding region of the
gene that is the area tested), and the genetic screening methods are
approximately 80% sensitive if sequencing is not used. Cases refer to
first-degree relatives or first/second-degree relatives if multiple cases.
Data from [7••,16,19,21,23,25,72].is now thought that BRCA1 and BRCA2 may mend
double-strand breaks, and they colocalize with rad51 [31•].
We have preliminary data from normal fibroblast clono-
genic radiation survival curves and DNA repair assays that
BRCA1 carriers are not more radiosensitive and are not
DNA repair deficient when compared with related noncarri-
ers from the same family [32] (unpublished data), but those
studies were based on doses equivalent to those used in
therapy rather than screening, and the numbers are very
small (six carriers). There are no human radiosensitivity data
for BRCA2 heterozygous normal cells.
The teaching of breast awareness is practiced in many
breast clinics that manage BRCA1 and BRCA2 mutation
carriers, and studies in the general population [33] have
shown that it downstages nodal status in tumours at pre-
sentation, but it does not appear to reduce mortality.
Alternative methods of breast imaging are being assessed
in BRCA1 and BRCA2 mutation carriers and in women of
unknown mutation status in high-risk families using mag-
netic resonance imaging of the breast with gadolinium
contrast enhancement [34]. Breast magnetic resonance
imaging has some potential advantages because it does
not use irradiation and is more sensitive than mammogra-
phy. There is also concern that BRCA1-associated breast
cancers have a lower proportion of ductal carcinoma in
situ than those in BRCA2 carriers [35•], and therefore
they may be less easily detected on mammography.
Ovarian screening
This is more controversial because ovarian screening in high-
risk women has not yet been shown to reduce mortality,
although a population-based study [36] showed a mortality
reduction (P=0.0112). There is an ongoing United Kingdom
Coordinating Committee for Cancer Research trial of ovarian
screening with annual transvaginal ultrasound and CA125
measurement in women with at least two cases of ovarian
cancer or breast and ovarian cancer in their family history.
BRCA1 and BRCA2 carriers can be entered into this study.
Screening is started at age 30 years for BRCA1 and at 35
years for BRCA2 mutation carriers because of the later start
of rise in level of ovarian cancer risk for BRCA2.
Prostate screening
Targeted prostate cancer screening in first-degree rela-
tives of brother pairs with the disease has demonstrated a
higher detection rate of prostate cancer than expected
[37], but whether there is a reduction in mortality is uncer-
tain. A study of prostate-specific antigen and digital rectal
examination screening in male carriers of BRCA1 and
BRCA2 is being proposed (Eeles et al, unpublished data).
Other cancers
From Table 1, there is also a risk for colon cancer in
BRCA1 carriers, but in families with multiple cases of
colon cancer colonoscopic screening is only offered if the
lifetime risk is greater than 10%. Furthermore, there is an
increased incidence of right-sided colonic tumours in
hereditary nonpolyposis colorectal cancer families [38]. In
BRCA1 carriers, the lifetime risk is 6%, and it is unknown
whether there is a side predilection for these tumours. If
studies confirm the increased risk for colon cancer and
show it to be left sided, sigmoidoscopy screening may
suffice. This is a question that needs to be answered. The
risk for male breast cancer in BRCA2 carriers is small (5%
lifetime), but is still 100-fold that in the general population.
Mammography is not feasible and may not be warranted
anyway at this level of risk, and self-examination is sug-
gested. Male breast cancer in BRCA2 carriers is very rare
in those aged less than 50 years.
Carriers of mutations in the BRCA2 gene are also at risk for
other cancers. The absolute lifetime risks are very low, but
one cancer that can be monitored by the carrier is cuta-
neous melanoma. There should be a low threshold for exam-
ination of any suspicious skin lesions by a dermatologist.
Changes in lifestyle
A number of lifestyle factors have been shown to influence
the development of breast cancer in the general popula-
tion, although most of these have not been specifically
investigated in BRCA1 and BRCA2 mutation carriers. The
factors that have been shown to affect female breast
cancer risk in the general population but that have not been
investigated in BRCA1 and BRCA2 carriers are diet,
alcohol intake, exercise and hormone replacement therapy.
Smoking has been shown to reduce breast cancer in
BRCA1 and BRCA2 carriers, probably due to an antioe-
strogenic effect [39], but its carcinogenic properties at
other sites precludes its use to reduce breast cancer risk.
The oral contraceptive pill (OCP) reduces the risk for
ovarian cancer in BRCA1 and BRCA2 carriers to the same
degree as in the general population, but its effect on breast
cancer risk has not yet been reported. Modelling of breast
and ovarian cancer mortality without any surgical interven-
tion is difficult to achieve because it is unknown whether
the risk of breast cancer in BRCA1 and BRCA2 carriers
who take the OCP is the same as that in the general popu-
lation. If a prophylactic oophorectomy is performed,
however, this has been shown [40•,41•] to reduce both
breast and ovarian cancer risk, and if use of the OCP
raised breast cancer risk it could theoretically be disadvan-
tageous to take the OCP because the reduction in ovarian
cancer risk could be provided by the surgical option. Early
age at first pregnancy does not seem to offer protection
from breast cancer, unlike in sporadic disease [42].
Chemoprevention
The role of tamoxifen prevention is discussed at length in
another review in the present issue [43]. In brief, tamoxifen
may reduce the incidence of breast cancer in the white
Breast Cancer Research    Vol 2 No 4 EelesAmerican population by 45% [44••], but two further publi-
cations [45••,46••] have failed to show this effect. It is pos-
sible that the studies used different populations of women
with different familial cancer risks, which may have
affected the outcomes of the trials. Theoretically, chemo-
prevention with tamoxifen may be less effective in BRCA1
carriers, because their tumours are more likely to be
oestrogen receptor negative [35•].
Prophylactic surgery
Prophylactic mastectomy to reduce breast cancer risk is
increasingly being offered to carriers of BRCA1 and
BRCA2 mutations. The uptake of this option is lower in the
USA [47] than in the UK [48] and Holland [49]. Its efficacy
is unproven, but retrospective data [50••] have suggested
that there is a 90% reduction in mortality. Prophylactic
oophorectomy reduces mortality from ovarian cancer [40•],
and also from breast cancer in BRCA1 and BRCA2 carri-
ers [41•]. There has been a reported case of a male having
prophylactic mastectomy [51]; he was at a one in two risk in
a BRCA2-like family in which no mutation could be found.
His lifetime breast cancer risk was, in fact, only 2.5%, which
is lower than the general population female breast cancer
risk. This highlights the issue that levels of anxiety weigh
heavily in the decision-making process to proceed with pro-
phylactic surgery, and may be more influential than the
absolute level of risk [52]. Because of the body-image
issues surrounding prophylactic mastectomy, it is recom-
mended that individuals who are considering prophylactic
mastectomy should be offered a protocol of a cancer genet-
ics risk assessment, a clinical psychological assessment,
and consultations with the breast surgeon and clinical nurse
specialist in breast care. This should include being shown
photographs of good and poor cosmetic results, and the
breast surgeon should either have extensive experience in
reconstructive surgery or work closely with a plastic surgeon.
The type of mastectomy offered will depend on the
woman’s physique and preference. For prophylaxis, as
much as possible of the breast tissue is removed, and
either an implant is inserted or a tram flap is used (the
muscle of the flap replacing the breast tissue). There is no
evidence that silicone implants are associated with an
increased cancer risk [53]. Prospective studies of the effi-
cacy of these operations are needed.
Prophylactic oophorectomy reduces the risk of ovarian
cancer [40], but cancer can still occur in the peritoneum
because these cells have the same embryological origin
as those on the surface of the ovary. The chance of this
occurring is uncertain, but may be as low as 2–3% [54].
Management of affected BRCA1 and BRCA2
mutation carriers
The following issues have to be considered in the man-
agement of a BRCA1 and BRCA2 mutation carrier who is
affected with cancer: is the tumour pathology any different
and does this impact upon management of the tumour?; is
the survival from the cancer any different?; issues sur-
rounding radiosensitivity or chemosensitivity; screening for
second primary cancers; and prophylactic surgery.
Tumour pathology, and impact on management and
survival
Breast cancer in BRCA1 mutation carriers tends to be of
higher grade and to have a higher proportion of atypical
medullary cancer and a lower proportion of carcinoma in
situ [55]. BRCA2 has a lower rate of tubule formation,
which is a bad prognostic feature [35•]. Mutiple regres-
sion of the pathological features of the breast cancers in
BRCA1 and BRCA2 mutation carriers shows that the
main pathological predictor of BRCA1 is mitotic count,
lymphocytic infiltration and continuous pushing margins,
but not the medullary phenotype per se. This would
predict that the survival from breast cancer in BRCA1 car-
riers would be worse, but studies of survival from breast
cancer in BRCA1 carriers show conflicting results. Thirty-
one studies related to survival from breast cancer and
familial factors were reported between 1996 and 1999;
these were summarized in a review by Chappuis et al
[56••]. These were divided into family history studies,
linkage studies and mutation-based studies. Of the family
history studies (18 studies in total), four showed a better
survival in individuals with a family history than in those
without, two showed worse survival and the rest showed
no difference. In the linkage studies (three studies in total),
two families linked to BRCA1 had a better survival and
one linked to BRCA2 had a worse survival relative to the
general population. Finally, in the mutation-based studies
(10 studies in total), eight showed no difference and two
showed a worse outcome in mutation carriers relative to
those in the general population.
No study conclusively proves that survival is improved in
BRCA1 carriers. The problem with these studies is that
there is inherent bias because most mutation detection
has to be performed on DNA from blood, and the woman
with breast cancer therefore have to be alive to be tested.
This can partly be overcome in two ways; the first is to
ignore the proband that was tested in the survival analysis.
When this was done in the study by Verhoog et al [57],
the survival changed from no difference to a worse survival
in BRCA1 carriers, although this was not statistically sig-
nificantly different. The second method is to take stored
breast cancer tumour material from all patients and test for
BRCA1/BRCA2 mutations. This is currently only feasible
in a population such as the Jewish population in which the
entire gene does not have to be screened for mutations,
because they have three common founder mutations in
BRCA1/BRCA2; such studies by Foulkes et al [58] and
Lee et al [59] in Jewish women showed no difference in
survival. Only the studies in Jewish women and another
http://breast-cancer-research.com/content/2/4/283study by Verhoog et al [60] have studied survival in
women with breast cancer due to BRCA2 mutations.
These suggest that the survival from breast cancer in
BRCA2 carriers is the same as in the general population.
Such tumours tend to be oestrogen receptor positive; this
feature is a good prognostic factor in sporadic patients.
If BRCA1-associated breast cancer has a worse progno-
sis, it may be important to offer radical therapy even to
those with very early tumours. For example, this may be a
group in which even very small (<1 cm) grade 3 tumours
should be treated with adjuvant chemotherapy, an area in
which at present there is controversy about the role of
adjuvant chemotherapy [61].
Robson et al [62] have shown that women with founder
BRCA1/BRCA2 Jewish mutations are at increased risk
for ipsilateral breast cancer-related events after breast
conservation, although this was not statistically significant.
There is a statistically significant increased contralateral
breast cancer risk (relative risk 3.50, 95% confidence
interval 1.78–8.74; P=0.001). Oncologists are consider-
ing the appropriateness of conservative management in
view of such results. As yet, the data are not strong
enough to prove bilateral mastectomy as the management
of choice, but studies of follow up of carriers such as
those being conducted by Easton, Goldgar and Narod,
within the BCLC, will help to answer this question.
There are data that suggest that survival is worse in
ovarian cancer that occurs in familial cases with or without
an association with BRCA1/BRCA2 mutations [63–67].
Issues surrounding radiosensitivity or chemosensitivity
It is not yet known whether tumours in BRCA1 or BRCA2
mutation carriers have a different sensitivity to DNA dam-
aging agents. Mice that are brca1 or brca2 null have
increased radiosensitivity and chemosensitivity [68–70],
but human BRCA1 heterozygote fibroblasts do not seem,
on preliminary data, to have an increased radiosensitivity
[32]. It should, however, be emphasized that the human
data are based on very small numbers and are for high
dose rate irradiation of fibroblasts only. This does not
provide data on BRCA2 or low dose rate irradiation.
Screening for second primary cancers and prophylactic
surgery
After cancer development in a BRCA1 or BRCA2 muta-
tion carrier, they are at risk for second primary cancers.
The risk for development of a second primary breast
cancer after the first breast cancer in women is 64% and
56% lifetime in BRCA1 and BRCA2 mutation carriers,
respectively [7••]; the balance of risk of cancer recurrence
from the first primary and risk of a second cancer therefore
needs to be considered in the management of the individ-
ual carrier with cancer. Prophylactic surgery for the risk of
certain second cancers can also be used to help with
treatment of the first primary cancer; it has been shown
that oophorectomy improves survival from breast cancer in
large meta-analyses [71]. Such surgery can therefore be
used as part of the treatment of the first cancer to improve
survival, and reduce risk of a subsequent new cancer.
Conclusion
The cancer risk profile of BRCA1 and BRCA2 mutation
carriers is becoming clearer, although uncertainties still
exist regarding the differences between ethnic groups, the
extent of genotype–phenotype interactions, the influence of
environment on phenotypic expression and the effect of
genotype on outcome after cancer treatment. The relative
rarity of BRCA1 and BRCA2 carriers means that the study
of these questions will necessarily be in large multicentre,
international trials. The discovery of other breast cancer
predisposing genes that may be more prevalent and of
lower penetrance will result in the development of tailored
treatment and prevention strategies for oncology patients
according to their cancer-predisposing genetic profile.
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